'Michael' moonwalks to $97 million opening, shattering record for music biopics

"Michael" debuted with $97 million in U.S. and Canada theaters and $217.4 million globally, setting a new record opening for a music biopic and far exceeding pre-release estimates of about $50 million to $70 million. Despite poor reviews and a rocky production involving costly reshoots, audience response was strong, with an A- CinemaScore versus 38% on Rotten Tomatoes. The strong launch boosts Lionsgate’s box-office performance and supports plans for sequels.

Analysis

The key read-through is not just that one title overperformed, but that theatrical demand can still be highly elastic when a film becomes a true event. That matters for exhibitors and content owners because it improves the math on premium formats, ancillary concession spend, and the bid for tentpole scheduling; the second-order beneficiary is anyone with a robust release slate and leverage to distribution windows. The result also implies the market may be underestimating the terminal value of legacy IP when paired with a recognizable music catalog and a broad four-quadrant audience.

For distributors and studios, the bigger signal is that marketing ROI can be dramatically convex when opening-weekend awareness tips from curiosity to must-see behavior. That favors companies with the balance sheet to absorb elevated P&A or production overruns, while punishing smaller players forced to compete for screens against a title that can sustain multiple weeks of elevated attendance. If this momentum holds, it should strengthen bargaining power with exhibitors and support a richer mix of sequelization and catalog exploitation over the next 6-18 months.

The contrarian risk is that this is a title-specific phenomenon driven by nostalgia and controversy, not a clean read on broad box-office health. If the second and third weekends normalize sharply, the market may overstate the durability of music-biopic demand and underappreciate how much upside was pulled forward by a novelty spike. The litigation/estate sensitivity also creates a tail risk for downstream installments: any narrative or legal pushback could compress sequel economics even if the first film’s opening looked exceptional.

Key Decisions for Investors

• Long exhibitors with premium-format exposure on a 1-3 month view; use AMC/CNK as a trade expression only if liquidity and borrow are acceptable. Risk/reward: upside if event titles keep driving attendance and concession mix, but trim quickly if weekend-2 drop-off exceeds ~60%.
• Overweight studios/distributors with large IP libraries and financing scale versus small-cap content names for the next 6-12 months. Favor a basket approach over single-name risk; the market should reward balance-sheet strength and franchise monetization capacity.
• Pair trade: long high-quality content owners / short weaker independent producers that rely on one-shot theatrical hits. Thesis is that the winner set is widening as only companies with distribution reach and capital can absorb production surprises and still participate in upside.
• If exposed to media names with material legal/estate overhangs, buy downside protection over the next 3-6 months. The tail risk is not opening weekend, but a later narrative reset that can impair sequel optionality and collapse expected NPV.
• Monitor the second-weekend multiple before adding risk. If hold is unusually strong, add on confirmation; if the drop is steep, fade the enthusiasm and rotate out of event-driven exposure into broader consumer discretionary names.